Adagene

Adagene(ADAG)

JIANGSU, China
Biotechnology

Focus: Antibody discovery & engineering

Adagene is a life sciences company focused on Antibody discovery & engineering.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Clinical Trials (1)
NCT05277402ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Phase 1
Clinical Trials (1)
NCT05614258Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT03802955Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Phase 1
Clinical Trials (1)
NCT03707093Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Phase 1
Clinical Trials (1)
NCT04501276A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Phase 1
Phase 1
Clinical Trials (1)
NCT04111445Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Phase 1
Clinical Trials (1)
NCT05236608A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
Phase 1/2
Clinical Trials (1)
NCT05405595ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Phase 1/2
ADG106 injection
Solid Tumor
Phase 1/2
Clinical Trials (1)
NCT04775680Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Phase 1/2
Clinical Trials (1)
NCT05275777A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
Phase 1/2
Phase 1/2
Pembrolizumab & ADG106
Advanced Solid Tumor
Phase 1/2
Clinical Trials (1)
NCT05491083Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
Phase 1/2
Clinical Trials (1)
NCT04645069ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Phase 1/2
Clinical Trials (1)
NCT06846268Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 13 clinical trials
Top TAs: Oncology
Publications: 10 in PubMed
Therapeutic Area Focus
Oncology
13 pipeline
Marketed
Pipeline